Price
Frequently asked questions
What is Cybin's market capitalization?
What is the Earnings Per Share (EPS) for Cybin?
What are the analyst ratings and target price for Cybin's stock?
What is the EBITDA for Cybin?
What is the free cash flow of Cybin?
What is the 5-year beta of Cybin's stock?
How many employees does Cybin have, and what sector and industry does it belong to?
What is the free float of Cybin's shares?
Financials
Market Cap
$202.29M5Y beta
-0.00EPS (TTM)
-$6.17Free Float
18.72MEBITDA (TTM)
-$93.11MFree Cashflow (TTM)
-$72.06MPricing
Analyst Ratings
The price target is $190.21 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
50
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker